Join the premier forum for Hatch-Waxman litigators and pharmaceutical patent practitioners.
Gain Insights on Evolving Policies, Industry Trends, and Litigation Strategies
- Prepare for a New Administration
Timely analysis and insights on the new administration’s policy priorities and the projected impact on small molecule IP.
- Brand and Generic Focused Think Tanks
Explore the brand and generic point of view on how the small molecule manufacturers are evolving, emerging business concerns and litigation trends.
- View from the Bench
Our distinguished panel of District Court Judges will provide a closer look at the Paragraph IV litigation dockets.
Distinguished Chairs
Jamie Leeds
Vice President and Chief Patent Counsel – Hatch Waxman Litigation
Eli Lilly and Company
Cynthia Sun
Director, Legal Counsel
Meitheal Pharmaceuticals Inc.
Kathi Vidal
Partner
Winston & Strawn LLP
(Immediate past Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO)
Members of the Judiciary
Honorable Joshua Wolson
District Judge
United States District Court
Eastern District of Pennsylvania
(Visiting Judge, District of Delaware)
Honorable Stanley R. Chesler
District Judge
United States District Court
District of New Jersey
Honorable Tonianne J. Bongiovanni
Magistrate Judge
United States District Court
District of New Jersey
Key Conference Highlights
Status of the Inflation Reduction Act and Future Drug Price Negotiations
AI’s Impact on Drug Discovery and Patent Law
Focus on Litigation and Agency Decisions Following the Demise of the Chevron Doctrine in Loper V. Raimondo
Exploring the On-Sale Bar and Applicability of Prior Art
Orange Book Delisting Attempts
Navigating ODP and Patent Family Dynamics
3,700+
Attendees
560+
Speakers
110+
Sponsors
Network with In-House from Leading Brand Name and Generics
- Eli Lilly & Company
- Sanofi
- Genentech
- Daiichi Sankyo, Inc.
- Ferring Pharmaceuticals
- Nordic Pharma Inc.
- Meitheal Pharmaceuticals
- Bristol Myers Squibb
- Johnson & Johnson
Key Conference Takeaways
Hear from FDA, FTC and other key government agencies about regulatory and enforcement priorities
Meet over a dozen leading senior in-house patent counsel from brands and generics
Learn from a Chambers-ranked “who’s who” of the Hatch-Waxman bar from New York, DC, and Chicago
Who Should Attend
Patent attorneys and litigators (in-house & law firms) who represent:
- Brand name pharmaceutical companies
- Generic pharmaceutical companies
- Biopharmaceutical companies
Earn CLE/Ethics Credits
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.
Learn moreSponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein, Senior Business Development Manager
Phone: 201-282-7274
Email: [email protected]
